.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Harvard Business School
Colorcon
Merck
Citi
Healthtrust
Novartis
Cipla
Teva

Generated: July 22, 2017

DrugPatentWatch Database Preview

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) Drug Profile

« Back to Dashboard

What is the patent landscape for Doxorubicin Hydrochloride (liposomal), and when can generic versions of Doxorubicin Hydrochloride (liposomal) launch?

Doxorubicin Hydrochloride (liposomal) is a drug marketed by Dr Reddys Labs Ltd and Sun Pharma Global and is included in two NDAs.

The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.

Summary for Tradename: DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list19
Clinical Trials: see list3,713
Patent Applications: see list9,823
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) at DailyMed

Pharmacology for Tradename: DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION208657-001May 15, 2017ABRXNoNo► Subscribe► Subscribe
Sun Pharma Global
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION203263-002Feb 4, 2013ABRXNoYes► Subscribe► Subscribe
Dr Reddys Labs Ltd
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION208657-002May 15, 2017ABRXNoNo► Subscribe► Subscribe
Sun Pharma Global
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION203263-001Feb 4, 2013ABRXNoYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
McKinsey
Deloitte
Chinese Patent Office
Express Scripts
Harvard Business School
Cantor Fitzgerald
Covington
Novartis
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot